Treatment of HFD fed rats with liraglutide, a GLP-1 receptor agonist with potent anti-inflammatory property [93,94], for four weeks fully prevented HFD-induced muscle microvascular insulin resistance, restored small arterial vessel endothelial function, and improved insulin-stimulated glucose disposal [64]. This evidence concerns the gene GLP1R and Insulin resistance.